Lv3
392 积分 2023-06-19 加入
Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
9小时前
求助中
How I Treat: Secondary Acute Myeloid Leukemia
9小时前
已完结
Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions
6天前
已完结
A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
1个月前
已完结
Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia
2个月前
已完结
Population Pharmacokinetic and Exposure-Response Analysis to Support a Dosing Regimen of CPX-351 (NS-87) in Japanese Adult and Pediatric Patients with Untreated High-Risk Acute Myeloid Leukemia
3个月前
已关闭
The signaling pathways activated by ROR1 in cancer
4个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
4个月前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
4个月前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
4个月前
已完结
皖公网安备34019202002308
